A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Betaprodine
Metreleptin
The metabolism of Baricitinib can be increased when combined with Metreleptin.
Betaprodine
Armodafinil
The metabolism of Baricitinib can be increased when combined with Armodafinil.
Betaprodine
Sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Baricitinib.
Betaprodine
Roflumilast
Roflumilast may increase the immunosuppressive activities of Baricitinib.
Betaprodine
Siponimod
The risk or severity of adverse effects can be increased when Baricitinib is combined with Siponimod.
Betaprodine
Ibrutinib
The risk or severity of adverse effects can be increased when Ibrutinib is combined with Baricitinib.
Betaprodine
Bleselumab
The risk or severity of adverse effects can be increased when Baricitinib is combined with Bleselumab.
Betaprodine
Rozanolixizumab
The risk or severity of adverse effects can be increased when Baricitinib is combined with Rozanolixizumab.
Betaprodine
Risankizumab
The risk or severity of adverse effects can be increased when Baricitinib is combined with Risankizumab.
Betaprodine
Monomethyl fumarate
The risk or severity of adverse effects can be increased when Baricitinib is combined with Monomethyl fumarate.
Betaprodine
Tetrandrine
The risk or severity of adverse effects can be increased when Baricitinib is combined with Tetrandrine.
Betaprodine
Fluclorolone
The risk or severity of adverse effects can be increased when Baricitinib is combined with Fluclorolone.
Betaprodine
Fluperolone
The risk or severity of adverse effects can be increased when Baricitinib is combined with Fluperolone.
Betaprodine
Begelomab
The risk or severity of adverse effects can be increased when Baricitinib is combined with Begelomab.
Betaprodine
Fluocortin
The risk or severity of adverse effects can be increased when Baricitinib is combined with Fluocortin.
Betaprodine
9-(N-methyl-L-isoleucine)-cyclosporin A
The risk or severity of adverse effects can be increased when Baricitinib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Betaprodine
Hypericin
The risk or severity of adverse effects can be increased when Baricitinib is combined with Hypericin.
Betaprodine
Acteoside
The risk or severity of adverse effects can be increased when Baricitinib is combined with Acteoside.
Betaprodine
Deoxyspergualin
The risk or severity of adverse effects can be increased when Baricitinib is combined with Deoxyspergualin.
Betaprodine
Doxifluridine
The risk or severity of adverse effects can be increased when Baricitinib is combined with Doxifluridine.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3